Traduction de «set of indicators was then reviewed » (Néerlandais → Français) :

the performance of health systems can be found in Supplement S2 of this report. The whole set of indicators was then reviewed by the research team to avoid redundancies in indicators and enhance the consistency of the set.
The whole set of indicators was then reviewed by the research team to avoid redundancies in indicators and enhance the consistency of the set.

1.4 Methods to reach operational objectives Operational objective 1: To review the core set of 55 indicators, with a special focus on the 11 indicators for which there were no data in 2010.
The update of the former 55 indicators was made in a consensus meeting between the research team and a specialist in health indicators of the Federal Public Service (FPS) Public Health.

A dossier for EU approval of Afinitor (everolimus) in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis was also filed in July 2010; the FDA granted everolimus priority review for this indication. The FDA action date is October 29.
contre l’astrocytome sous épendymaire à cellules géantes associé à une sclérose tubéreuse; la FDA a accordé à évérolimus le statut de revue prioritaire pour cette indication, et sa décision est attendue pour le 29 octobre.

The continued strong growth in biosimilars was led by products such as Omnitrope, which has made steady gains against originator growth hormone deficiency treatments, as well as the launches of oncology indications of Binocrit (epoetin alfa) and Zarzio (filgrastim), setting the stage for further expansion of Sandoz’s position as the biosimilars market leader.
La forte progression continue des biosimilaires a été menée par des produits comme Omnitrope, qui na cessé de gagner du terrain face aux traitements originaux du déficit de l’hormone de croissance ainsi que par les lancements des indications oncologiques de Binocrit (époétine alfa) et Zarzio (filgrastim). Ainsi la voie est ouverte pour permettre à Sandoz de conforter sa position de leader du marché des biosimilaires.